Labcorp Holdings Inc
labcorp.comLabcorp Holdings Inc (NYSE: LH) is a clinical laboratory services company that provides diagnostic testing, drug development support, and biopharma laboratory services. The filing excerpts reference two primary business areas: clinical laboratory testing for patients and healthcare providers, and Biopharma Laboratory Services (BLS) supporting pharmaceutical and biotechnology clients. Labcorp operates within a heavily regulated environment governed by CLIA, HIPAA, HITECH, and the Affordable Care Act, among other federal and state frameworks. The company serves managed care organizations (MCOs), accountable care organizations (ACOs), independent physician associations (IPAs), and government payers. The filing also references Clinical Development and Commercialization Services (CDCS) and Companion Diagnostics (CDx) as service categories. The 10-K was filed on 2026-02-24 under accession number 000092014826000111. Specific revenue figures, segment breakdowns, headquarters details, founding year, and CEO tenure are not extractable from the provided filing excerpts and are therefore omitted.
Products & Services
Services referenced in the filing include clinical laboratory testing (laboratory-developed tests, or LDTs), Biopharma Laboratory Services (BLS), Clinical Development and Commercialization Services (CDCS), Companion Diagnostics (CDx), and Clinical Decision Support (CDS). Specific product names or brand details are not extractable from the provided excerpts.
Revenue Model
The filing excerpts reference transactional fee-for-service revenue from clinical laboratory testing billed to managed care organizations, government payers, and patients, as well as contract-based revenue from biopharma clients for laboratory and clinical development services. Specific revenue figures and segment percentages are not supported by the provided excerpts.
Customers & Markets
Customer types referenced in the filing include managed care organizations (MCOs), accountable care organizations (ACOs), independent physician associations (IPAs), pharmaceutical and biotechnology companies, and government health programs. End markets span clinical diagnostics and drug development support.
Geographic Exposure
The filing references U.S. regulatory frameworks as primary, with mention of Canadian Dollar (CAD) and U.K. Medicines and Healthcare Products Regulatory Commission (MHRA), indicating some international operations. Specific revenue by geography is not supported by the provided excerpts.
Loading...
